NHS Innovation Accelerator (NIA)
The NHS Innovation Accelerator, or NIA, supports uptake and spread of proven, impactful innovations across England’s NHS, benefitting patients, populations and NHS staff.

Ideas (Education, training and future workforce)

Innovation 'Elevator Pitch':
Digital behaviour change platform for people with type 2 diabetes and prediabetes providing goal-focused education, personalised resources and support to implement a lower carbohydrate lifestyle. 
Overview of Innovation:
The Low Carb Program is an award-winning digital health intervention for people with type 2 diabetes, prediabetes and obesity. The Low Carb Program provides the education, resources, and, most importantly, support required when reducing the amount of sugar (or carbohydrates) in the diet.

The platform is available in the NHS Apps Library and is an NHS Innovation Accelerator Fellow for 2019. The platform is QISMET approved to be provided as structured education for people with type 2 diabetes and prediabetes.
 
The platform comprises:
  • Education: members participate in a core 12-week structured therapeutic nutrition and wellness program, personalised to disease type and profile
  • Community peer support with over 400,000 members
  • Behaviour change mentoring, goal identification and setting
  • Library of personalised resources, including culturally-specific meal plans, food swaps and over 1,000 searchable recipe ideas
  • Data insights and AI-led feedback to support sustainable behaviour change
The Low Carb Program was developed with Dr David Unwin in 2015 (NHS Innovator of the Year 2016, RCGP National Champion for Collaborative Care in Obesity and Diabetes), and the feedback of 20,000 people with diabetes. 

DDM is conducting a three-year study on a randomly selected cohort of people who joined the Low Carb Program. One-year outcomes have been published in JMIR Diabetes with two-year outcomes are currently under review. The first evidenced benefit is a 71% platform retention at 1-year, which is unrivalled for any digital platform. Engagement within the platform is critical as without engaging users, behaviour change is not possible. The retention evidenced by the Low Carb Program is pioneering.
 
For people with type 2 diabetes who complete the platform, outcomes are:
  • 7.4kg weight loss
  • 13mmol/mol HbA1c reduction
  • 39% place HbA1c under type 2 diabetes threshold, with 26% placing type 2 diabetes 'in remission'
Remission is defined as an HbA1c under type 2 diabetes threshold and on no medication or metformin only.
 
In addition, to this:
  • 40% of people on medication eliminate at least one treatment from their regime
  • 60% of people on insulin eliminate or reduce it from their regime
The Low Carb Program has tiered licencing costs, with a patient licence cost of £90, which lasts 3 years. Given the affordability of the platform the Low Carb Program offers significant cost-savings from the perspective of reduced medication through improved patient health and reduced GP burden.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The Low Carb Program is scaling type 2 diabetes and prediabetes remission and benefits are most immediately seen in reduced medication dependency through improved HbA1c. A three-year study is underway on a randomly selected cohort of 1,000 people who joined the Low Carb Program. One-year outcomes have been published in JMIR Diabetes. The first evidenced benefit is a 71% platform retention at 1-year, which is unrivalled for any digital platform. Engagement within the platform is critical as without engaging users, behaviour change is not possible. The retention evidenced by the Low Carb Program is pioneering.
 
For people with type 2 diabetes who complete the platform, outcomes are:
  • 7.4kg weight loss
  • 13mmol/mol HbA1c reduction
  • 39% place HbA1c under type 2 diabetes threshold, with 26% placing type 2 diabetes 'in remission'
Remission is defined as an HbA1c under type 2 diabetes threshold and on no medication or metformin only.
In addition, to this:
  • 40% of people on medication eliminate at least one treatment from their regime
  • 60% of people on insulin eliminate or reduce it from their regime
A conservative cost-saving medication deprescription analysis was conducted on this cohort of users, and calculated at £835 per-patient, per-year in reduced medication deprescription savings.
 
Given the affordability of the platform, particularly when compared to competitors, the Low Carb Program offers significant cost-savings from the perspective of reduced medication through improved patient health and reduced GP burden.

There is clinical evidence of the Low Carb Program in practice, where it is being used with patients by NHS Symphony Healthcare health coaches with patients with type 2 diabetes in Yeovil in a blended care approach.

Currently, clinical data demonstrates improvements in HbA1c and weight for the majority of patients using the platform.
Benefits of engaging within the education are truly brought to life by many of the 400,000 members' stories, including:
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Adoption of the Low Carb Program will significantly improve patient and population health of people with type 2 diabetes and prediabetes in the West Midlands. 

Benefits are most immediately seen in reduced medication dependency through improved HbA1c. A three-year study is underway on a randomly selected cohort of 1,000 people who joined the Low Carb Program. One-year outcomes have been published in JMIR Diabetes. The first evidenced benefit is a 71% platform retention at 1-year, which is unrivalled for any digital platform. Engagement within the platform is critical as without engaging users, behaviour change is not possible. The retention evidenced by the Low Carb Program is pioneering.
 
For people with type 2 diabetes who complete the platform, outcomes are:
  • 7.4kg weight loss
  • 13mmol/mol HbA1c reduction
  • 39% place HbA1c under type 2 diabetes threshold, with 26% placing type 2 diabetes 'in remission'
Remission is defined as an HbA1c under type 2 diabetes threshold and on no medication or metformin only.
In addition, to this:
  • 40% of people on medication eliminate at least one treatment from their regime
  • 60% of people on insulin eliminate or reduce it from their regime
A conservative cost-saving medication deprescription analysis was conducted on this cohort of users, and calculated at £835 per-patient, per-year in reduced medication deprescription savings.
 
Given the affordability of the platform, particularly when compared to competitors, the Low Carb Program offers significant cost-savings from the perspective of reduced medication through improved patient health and reduced GP burden. 
Current and planned activity: 
The Low Carb Program is currently being showcased through the NHS Innovation Accelerator. It is also a member of the RCGP Innovation Mentorship Programme. Ascensia Diabetes Care lead implementation of the Low Carb Program within local areas once commissioned, including on-site healthcare professional training and support, patient onboarding resources and Key Manager 24/7 support. 
What is the intellectual property status of your innovation?:
All copyright and IP belongs to Diabetes Digital Media (DDM). Patents pending.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
ARJUN SINGH PANESAR 25/03/2019 - 13:30 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
CMC is an NHS urgent care planning service designed to capture a patient’s preferences for their care in one single version of the truth. The care plan is available digitally to all the clinicians involved in their care and emergency services 24/7.
Overview of Innovation:
The service was started in 2010 and currently serves Greater London. It is commissioned by the 32 London Clinical Commissioning Groups. There are currently over 50,000 CMC care plans in existence.
 
CMC fast facts:
  • The CMC service has been developed by NHS clinicians for NHS patients
  • Developed on the foundations of patient centric care, clinical integrity, information governance, data protection and security
  • Helps reduce unnecessary and unwanted hospital admissions, readmissions and associated ambulance transport costs and hospital stays
  • 76% of patient who have a CMC plan and place of death recorded, die in their place of choice
  • Where patients have a CMC care plan 19% died in hospital compared to the national average of 47% and 53.6% in London
  • Data suggest that the NHS saves on average £2,100 per patient who dies with a CMC care plan in place
  • For healthcare professionals it’s the confidence that the important and sensitive work they have documented with the patient is accessible to emergency services who may not know them as well
  • For patients it’s the knowledge that they are at the heart of planning and decision making around their own healthcare and that they will not need to repeat themselves repeatedly
 
The service is constantly evolving with an ongoing focus on interoperability with other healthcare IT systems and allowing patients to start to create their own care plan on a new patient portal myCMC. For more information please visit www.coordinatemycare.co.uk or call 020 7 811 8513.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The key benefits to the NHS include:
  • A higher quality of care for patients during the out of hours period with all the healthcare professional teams joined up and the patient's own preferences at the heart of the care delivered
  • Fewer unplanned hospital admissions and the associated costs with hospital stays
  • Lower costs with an estimated £2100 saved per patient with a CMC care plan
  • Meeting the NHS goals of digital, interoperable and paperless systems
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Similar benefits to London where we are established:
  • Greater connectivity of the multidisciplinary team working around the patient
  • Greater involvement of the patient in their own care delivery
  • An online care plan accessible to all healthcare professionals and emergency services representing one single version of the truth
  • Cost savings
Current and planned activity: 
Key priorities for Coordinate My Care include:
  • Interoperability with all GP, hospital and community IT systems
  • Taking CMC into wider regions across the UK
  • Supporting the myCMC patient portal for more patients to start their own care plans ratified by their clincians upon consultation
What is the intellectual property status of your innovation?:
The intellectual property of CMC has two components;
  1. The ‘wrap around’ that consists of teaching, training, monitoring, clinical and information governance, reporting and analytics. (Intellectual property of CMC/NHS)
  2. The IT platform on which the system is hosted and maintained (Intellectual property of InterSystems)
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Professor Julia Riley 07/03/2018 - 17:32 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
RespiraSense demonstrated a potential for 6-12 hours earlier detection of patient deterioration when compared to the standard of care. Putting that into context, for every 30-minute delay in treating Sepsis, increases the risk of mortality by 7%
Overview of Innovation:
RespiraSense is the world's only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, more so than heart rate if systolic blood pressure. In fact, 26 breaths per minute are considered the earliest point of divergence between Spo2 and respiratory rate. Giving rise to 12+hours of false security is accurate RR is not measured. 

The standard of care remains the manual counting of breaths per minute, which has been shown to be biased and prone to error. With evidence showing no change in the quality of measurements for over 170 years (1846SirHutchenson) (2017Badawy). 

RespiraSense gives medical teams the advantage of being able to intervene early, thus reducing time to intervention and improving outcomes. Outcomes such as Average Length of Stay, Average Unit Cost of Care, and Patient Safety targets can be achieved. 

RespiraSense is a simple, wireless, and discrete wearable monitor, placed on at admission and worn/measuring continuously for up to 7 days. Each patient receives a new sensor and a reusable electronic device or Lobe. See how the system works @ https://www.youtube.com/watch?v=u6KB1hBPQbM  
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Each year, there are approximately 500,000 admissions of Sepsis and Pneumonia with an average unit cost of £4,600 per admission. These two conditions are increasing in incidence and often lead to an escalation of care due to the risk of undetected deterioration. It's shown that a 5% reduction in the escalation of care of these two pathways alone, through the use of continuous Respiratory Rate monitoring triggering decreased time to interventions (Fluids, Oxygen, Antibiotics, Steroids), can reduce the average unit cost by £300 and the average length of stay by 0.5 days. This translates into a total Net cash saving of £115m and 250K bed days. Popular opinion suggests that as high as 20% reduction is achievable - Evidence pending. 

Each event prevented, having an average cost of £25,000, will pay for a whole year's supply of sensors for one year.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
West Midlands Trusts are driving the awareness of Sepsis through their ambulance services, patient awareness campaigns, and in-hospital initiatives. With 44,000 lives lost each year attributed to Sepsis, it is important to Prevent, Diagnosis Early, and Effectively Treat the condition. RespiraSense focused on the area of Diagnosis Early. Research suggests that NEWS2 is a more sensitive indicator of deterioration due to Sepsis than QSOFA. Both of which have Respiratory Rate as a critical parameter to measure. There is clinical and economical value in monitoring this essential vital sign accurately and clear additional benefit to having it monitored continuously. RespiraSense achieves both with low impact of False alarm due to its innovative design, boasting advanced motion-tolerance. 
Current and planned activity: 
PMD Solutions is working with Nursing Times to launch an educational campaign on the clinical science and importance of respiratory rate monitoring in acute care clinical practice. 

In addition, PMD Solutions is looking for Respiratory and Emergency teams to partner with and create a culture of Peer Leadership in the development of best practice for respiratory rate monitoring. 
What is the intellectual property status of your innovation?:
RespiraSense is positioned to be the new industry standard in respiratory rate monitoring. It is patented in Europe, United States, China, Hong Kong, and Japan. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Myles Murray 02/03/2018 - 21:21 Publish Login or Register to post comments
0
0
Votes
-99999

Recent Activities

Skin Analytics - DERM: AI for Skin Cancer has been moved from Initial Submission to Publish 1 month 1 week ago
My Diabetes My Way has been moved from Initial Submission to Publish 2 months 6 days ago
My Diabetes My Way has been moved from Detailed Submission to Publish 3 months 1 day ago
Scott Thornton voted on ChatHealth 3 months 1 week ago
ChatHealth has been moved from Initial Submission to Publish 3 months 1 week ago

Active Campaigns